These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 31737426)

  • 1. Advances and perspectives of PARP inhibitors.
    Yi M; Dong B; Qin S; Chu Q; Wu K; Luo S
    Exp Hematol Oncol; 2019; 8():29. PubMed ID: 31737426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    Faraoni I; Graziani G
    Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency.
    Zaman N; Kushwah AS; Badriprasad A; Chakraborty G
    Int Rev Cell Mol Biol; 2024; 389():257-301. PubMed ID: 39396849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    Vanacker H; Romeo C; Ray-Coquard I
    Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
    Bound NT; Vandenberg CJ; Kartikasari AER; Plebanski M; Scott CL
    Front Genet; 2022; 13():886170. PubMed ID: 36159999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of PARP inhibitor resistance and potential overcoming strategies.
    Fu X; Li P; Zhou Q; He R; Wang G; Zhu S; Bagheri A; Kupfer G; Pei H; Li J
    Genes Dis; 2024 Jan; 11(1):306-320. PubMed ID: 37588193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
    Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
    Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 14. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
    Javle M; Curtin NJ
    Ther Adv Med Oncol; 2011 Nov; 3(6):257-67. PubMed ID: 22084640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
    Han Y; Yu X; Li S; Tian Y; Liu C
    Front Oncol; 2020; 10():578095. PubMed ID: 33324554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
    McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic Induction of BRCAness in
    Abbotts R; Dellomo AJ; Rassool FV
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
    Noordermeer SM; van Attikum H
    Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
    Franchet C; Hoffmann JS; Dalenc F
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.